By Brittny Goodsell — Utah Business Magazine
David Bearss, CEO of Halia Therapeutics, says his company uses Carta to manage multiple things in the chronic inflammation biotech industry.
“Biotech companies are always in need of large capital raises to support the expenses from clinical development of new products and from the administrative side of the business,” he says.